Patel Sushil, Chief Executive Officer, Director at Replimune Group, Inc., sold $190K of REPL
This page documents an SEC Form 4 insider trading disclosure for $REPL securities filed with the Securities and Exchange Commission. Section 16 of the Securities Exchange Act of 1934 mandates that corporate officers, directors, and beneficial owners of more than 10% of a company's registered equity securities must report their personal trades within two business days of execution. Insider transactions are closely monitored by market participants because insiders possess firsthand knowledge of company operations, financial condition, and near-term prospects. The transaction details below are drawn directly from the SEC EDGAR filing database and reflect the information as reported.
Transaction Details
| Insider | Patel Sushil |
|---|---|
| Title | Chief Executive Officer, Director |
| Company | Replimune Group, Inc. |
| Ticker | REPL |
| Transaction Type | Sale |
| Transaction Date | 2026-05-18 |
| Shares Traded | 37,324 |
| Price Per Share | $5.08 |
| Total Value | $190K |
| Filed Date | 2026-05-20 |
| Accession Number | 0001104659-26-064519 |
Ownership Context
| Shares Owned After Transaction | 747,492 |
|---|---|
| Ownership Type | Direct |
SEC Filing
Accession: 0001104659-26-064519
Other Insider Trades — REPL
| Insider | Title | Action | Value | Date |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Insider | bought | $31.5M | 2026-08-11 |
| BAKER BROS. ADVISORS LP | Insider | bought | $1.5M | 2026-08-11 |
| Sarchi Christopher | Chief Commercial Officer | sold | $111K | 2026-06-01 |
| Sarchi Christopher | Chief Commercial Officer | sold | $44K | 2026-05-18 |
| Schwendenman Andrew | Chief Accounting Officer | sold | $40K | 2026-05-18 |
| Xynos Konstantinos | Chief Medical Officer | sold | $71K | 2026-05-18 |
| Hill Emily Luisa | Chief Financial Officer | sold | $40K | 2026-05-18 |
| Astley-Sparke Philip | Director | sold | $90K | 2026-05-18 |
| Sarchi Christopher | Chief Commercial Officer | sold | $52K | 2026-04-02 |
| Patel Sushil | Chief Executive Officer, Director | traded | — | 2026-04-01 |
Other Trades by Patel Sushil
| Ticker | Company | Action | Value | Date |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | sold | $104K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $170K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | traded | $111K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $55K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $166K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $204K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $160K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $19K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | sold | $114K | 2026-06-29 |
| RVMD | Revolution Medicines, Inc. | traded | — | 2026-06-18 |
Full Ticker Profile
View all insider trades, dark pool activity, congressional filings, and the Whisper Score for REPL — Replimune Group, Inc. →
Whisper Score — REPL
Track REPL insider activity in real time on The Wire →
Get alerts when Patel Sushil files new trades — Go Pro →
Data sourced from SEC Form 4 insider trading filings. Transaction details are as reported to the Securities and Exchange Commission. This page does not constitute financial advice. StonkWhisper presents public records — it does not verify or guarantee the accuracy of SEC filings.
Last updated: August 12, 2026 at 07:27 UTC